MAXCYTE, INC. — Investor Relations & Filings
MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | |
| SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | |
| SCHEDULE 13G Filing | 2026-02-05 | English | |
| 8-K Filing | 2026-01-12 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| 10-Q | 2025-11-13 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 33065964 | 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | ||
| 33061623 | SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | ||
| 28677652 | SCHEDULE 13G Filing | 2026-02-05 | English | ||
| 28677654 | 8-K Filing | 2026-01-12 | English | ||
|
2025
11 filings
| |||||
| 11680606 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 11680607 | 10-Q | 2025-11-13 | English | ||
| 11680611 | 8-K | 2025-11-12 | English | ||
| 11680609 | 8-K | 2025-11-05 | English | ||
| 11680608 | Major Shareholding Notification 2025 | 2025-11-04 | English | ||
| 11680610 | Major Shareholding Notification 2025 | 2025-11-03 | English | ||
| 11680612 | Major Shareholding Notification 2025 | 2025-10-24 | English | ||
| 11680613 | 8-K | 2025-09-22 | English | ||
| 11680614 | Director's Dealing 2025 | 2025-08-27 | English | ||
| 11680615 | FORM S-8 | 2025-08-26 | English | ||
| 11680616 | Director's Dealing 2025 | 2025-08-13 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
|
IMUGENE LIMITED
Clinical-stage immuno-oncology company developing cancer im…
|
IMU | AU | Professional, scientific and te… |
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
MAXCYTE, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/10520/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=10520 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=10520 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=10520 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 10520}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MAXCYTE, INC. (id: 10520)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.